Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells

In Vivo

Volumn 19, Issue 1, 2005, Pages 237-246

  Sung, Fion Lan ^a   Poon, Terence Cheun Wai ^a   Hui, Edwin Pun ^a   Ma, Brigette Buig Yue ^a   Liong, Eleanore ^a   To, Ka Fai ^a   Huang, Dolly Poon Wai Sin ^a   Chan, Anthony Tak Cheung ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti epidermal growth factor receptor monoclonal antibody; Cetuximab; Cisplatin; Nasopharyngeal carcinoma; Paclitaxel

Indexed keywords

BIOLOGICAL MARKER; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; NASOPHARYNX CARCINOMA; PREDICTION; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 16244371388     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hong Kong Cancer Registry 2001. Hospital Authority, Hong Kong Special Administrative Region, PRC, http://www3.ha.org.hk/cancereg/.
2. Chan AT, Teo PM and Johnson P J: Nasopharyngeal cancer. Cancer Treat Res 114: 275-293, 2003.
3. Chan AT, Teo PM, Leung TW and Johnson PJ: The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer 82 1003-1012, 1998.
4. Hui EP, Leung SF, Au JS, Zee B, Tung S, Chua D, Sze WM, Law CK, Leung TW and Chan AT: Lung metastasis alone in nasopharyngeal carcinoma: a relatively favorable prognostic group. A study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Cancer 101: 300-6, 2004.
5. Ciardiello F and Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958-2970, 2001.
6. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20: 1S-13S, 2002.
7. Zheng X, Hu L, Chen F and Christensson B: Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 30B: 290-295, 1994.
8. Roychowdhury DF, Tseng A, Jr, Fu KK, Weinburg V and Weidner N: New prognostic factors in nasopharyngeal carcinoma. Tumor angiogenesis and C-erbB2 expression. Cancer 77: 1419-1426, 1996.
9. Sheen TS, Huang YT, Chang YL, Ko JY, Wu CS, Yu YC, Tsai CH and Hsu MM: Epstein-Barr virus-encoded latent membrane protein 1 co-expresses with epidermal growth factor receptor in nasopharyngeal carcinoma. Jpn J Cancer Res 90: 1285-1292, 1999.
10. Fujii M, Yamashita T, Ishiguro, R, Tashiro M and Kameyama K: Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 29: 175-181, 2002.
11. Putti TC, To KF, Hsu HC, Chan AT, Lai GM, Tse G, Lee YS, Whang-Peng J, Millward M, Lin L, Lin X and Lee CS: Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 41: 144-151, 2002.
12. Leong JL, Loh KS, Putti TC, Goh BC and Tan LK: Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 114: 153-157, 2004.
13. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ and Chan AT: Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study. Head Neck 25: 864-872, 2003.
14. Chua DT, Nicholls JM, Sham JS and Au GK: Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 59: 11-20, 2004.
15. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
16. Fan Z, Baselga J, Masui H and Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53: 4637-4642, 1993.
17. Huang SM, Bock JM and Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59: 1935-1940, 1999.
18. Huang SM and Harari PM: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6: 2166-2174, 2000.
19. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR and Tortora G: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 5: 909-916, 1999.
20. Inoue K, Slaton JW, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, McConkey DJ, Sweeney P, Radinsky R and Dinney CP: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 6: 4874-4884, 2000.
21. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW and Hicklin DJ: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8 994-1003, 2002.
22. Sizhong Z, Xiukung G and Yi Z: Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma. Int J Cancer 31: 587-590, 1983.
23. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, Wen DS and Li YP: Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci USA 86: 9524-9528, 1989.
24. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, Wong N, Whitney BM and Lee JC: Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 83: 121-126, 1999.
25. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, Li CL, Mak LS, Lai SH and Lau WH: Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 26 127-132, 1980.
26. Maity A, Pore N, Lee J, Solomon D and O'Rourke DM: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60: 5879-5886, 2000.
27. Twentyman PR and Luscombe M: A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 56: 279-285, 1987.
28. Loveland BE, Johns TG, Mackay IR, Vaillant F, Wang ZX and Hertzog PJ: Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays. Biochem Int 27: 501-510, 1992.
29. Janmaat ML, Kruyt FA, Rodriguez JA and Giaccone G: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9: 2316-2326, 2003.
30. Chan AT, Teo PM and Johnson PJ: Controversies in the management of locoregionally advanced nasopharyngeal carcinoma. Curr Opin Oncol 10: 219-225, 1998.
31. Grunwald V and Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95: 851-867, 2003.
32. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J and Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208, 2004.
33. Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D and Zeng YX: EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett 169 27-32, 2001.
34. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 1497-1500, 2004.
35. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
36. Mendelsohn J and Fan Z: Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89: 341-343, 1997.
37. Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward M, Chang AY, Ma BB, Hong RL and Lin X: A phase II study of cetuximab (C225) in combination with carboplatin in patients (pts) with recurrent or metastatic nasopharyngeal carcinoma (NPC) who failed to a platinum-based chemotherapy. Proc Am Soc Clin Oncol 22: 4497(abstr 2000), 2003.